Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Multicenter Phase II Extension of Study 28063 (ATAMS) to Obtain Long-term Follow-up Data in Subjects With Relapsing Multiple Sclerosis Treated With Atacicept for up to 5 Years (ATAMS-Extension)
Brief Summary: This study (28851) is a long-term follow-up study of subjects enrolled in ATAMS study 28063 (NCT00642902). The aim of this study is to monitor the safety and tolerability of atacicept administered for up to 5 years to subjects with relapsing multiple sclerosis (RMS).

This extension study consists of two parts. Part A will be double blind and Part B will be open label. During Part A, subjects initially randomized to atacicept will continue to receive the atacicept dose to which they have been randomized in study 28063 (ATAMS) once a week subcutaneously (under the skin). Subjects randomized to placebo in ATAMS will receive atacicept at 150 mg once a week subcutaneously during Part A. Once the results of ATAMS are available and the atacicept dose with the best benefit / risk ratio has been identified, all subjects will be switched to this dose and will continue the extension study open-label (Part B). Throughout the study, subjects and investigators will remain blinded with respect to initial and part A treatment allocation/dose.


Options:
A: Arm Label: Glatiramer acetate; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer Acetate (DB), Drug: Glatiramer Acetate (OL) | Arm Label: Placebo (DB) to GA (OL); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Glatiramer Acetate (OL) | Intervention Type: DRUG; Name: Glatiramer Acetate (DB); Assigned to Arm(s): Glatiramer acetate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (DB) to GA (OL) | Intervention Type: DRUG; Name: Glatiramer Acetate (OL); Assigned to Arm(s): Glatiramer acetate, Placebo (DB) to GA (OL)
B: Arm Label: GTR; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer Acetate (GTR) | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate (Copaxone®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate (GTR); Assigned to Arm(s): GTR | Intervention Type: DRUG; Name: Glatiramer Acetate (Copaxone®); Assigned to Arm(s): Copaxone® | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Laquinimod; Type: EXPERIMENTAL; Interventions: Drug: Laquinimod | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Laquinimod; Assigned to Arm(s): Laquinimod | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Atacicept 25 mg (With Loading); Type: EXPERIMENTAL; Interventions: Drug: Atacicept 25 mg | Arm Label: Atacicept 75 mg (With Loading); Type: EXPERIMENTAL; Interventions: Drug: Atacicept 75 mg | Arm Label: Atacicept 150 mg (With Loading); Type: EXPERIMENTAL; Interventions: Drug: Atacicept 150 mg | Arm Label: Atacicept 150 mg (Without Loading); Type: EXPERIMENTAL; Interventions: Drug: Atacicept 150 mg | Intervention Type: DRUG; Name: Atacicept 25 mg; Assigned to Arm(s): Atacicept 25 mg (With Loading) | Intervention Type: DRUG; Name: Atacicept 75 mg; Assigned to Arm(s): Atacicept 75 mg (With Loading) | Intervention Type: DRUG; Name: Atacicept 150 mg; Assigned to Arm(s): Atacicept 150 mg (With Loading) | Intervention Type: DRUG; Name: Atacicept 150 mg; Assigned to Arm(s): Atacicept 150 mg (Without Loading)

Answer: D